不同剂量顺铂的联合化疗方案治疗非小细胞肺癌

Combination Chemotherapy Regimens Containing Varied Dosage of Cisplatin forNon-Small Cell Lung Cancer

作者采用不同剂量顺铂为主的联合方案治疗晚期非小细胞肺癌１４６例。其中小剂量顺铂组用法为２０～３ｏｍｇ／次×３～５天；中剂量顺铂组为４０～６０ｍｇ／次×２～５天；大剂量顺铂组为７０～１００ｍｇ／次×１天。结果：小、中、大剂量顺铂组的疗效（完全缓解＋部分缓解）分别为３５．９２％（３７／１０３）、３６．９６％（１７／４６）和４０．９１％（９／２２），三组间无显著性差异（Ｐ＞０．０５）。中剂量顺铂组肾毒性较低（Ｐ＜０．０５）。提示以中剂量顺铂为主的联合方案治疗晚期非小细胞肺癌疗效较好，肾毒性较低，是值得推荐的治疗方案。

One hundred and forty six patientswith non-small cell lung cancer(NSCLC)were treat-ed with combination chemotherapy regimens contain-ing different dosage of cisplatin. Low dose group:cisplatin was used intravenously at a dose of 20～30mg daily for 3～5days;Middle dose group:cis-platin was used intravenously at a dose of 40～60mgdaily for 2～5days;High dose group:cisplatin wasused intravenously at a dose of 70～100mg/m￣2 for 1day.The response rates(complete response plus par-tial response)of three groups were 35.92%,36.96%and 40. 91%respectively.There was no significantdifference in the therapeutic effects among threegroups (P>0.05).But the renal toxicity occured inmiddle dose cisplatin group was lower than other twogroups (P≤0. 05 ).It is suggested that using middledose cisplatin in combination chemotherapy is morebeneficial to patient than others.